Gemcitabine in the treatment of metastatic pancreatic cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 511-523

  Hilbig, Andreas ^a   Oettle, Helmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gemcitabine; Palliative; Pancreatic carcinoma; Targeted therapy; Therapy; Treatment

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTARABINE; DNA; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LAROTAXEL; MATRIX METALLOPROTEINASE INHIBITOR; NEW DRUG; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RUBITECAN; SORAFENIB; TAXANE DERIVATIVE; TIPIFARNIB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESOPHAGUS INJURY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INOPERABLE CANCER; INTESTINE PERFORATION; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENOMICS; REVIEW; SENSORY NEUROPATHY; STRUCTURE ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; INTRAVENOUS DRUG ADMINISTRATION; PANCREAS TUMOR; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 43049183349     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.511     Document Type: Review

References (114)

1. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 45, 1857-1861 (1997).
2. Allerheiligen S, Johnson R, Hatcher B et al. Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc. Ann. Meeting Am. Soc. Clin. Oncol. 338 (1994) (Abstract 13).
3. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol. Cancer 2(6), 1-14 (2003).
4. Ferreira CG, Span SW, Peters GF et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 60, 7133-7141 (2000).
5. Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J. Gastrointest. Surg. 8, 1072-1078 (2004).
6. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer 97, 145-151 (2007).
7. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
8. Carmichael J, Fink U, Russell RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73(1), 101-105 (1996).
9. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2′,2′-difluoro 2′-deoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12(1), 29-34 (1994).
10. Hochster HS. Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. Int. J. Radiat. Oncol. Biol. Phys. 56(Suppl.4), 24-30 (2003).
11. Touroutoglou N, Gravel D, Raber MN et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol. 9(9), 1003-1008 (1998).
12. Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21(18), 3402-3408 (2003).
13. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J. Clin. Oncol. 24(Suppl. 18), 4004 (2006).
14. Ko AH, Dito E, Schillinger B et al. A Phase II study of gemcitabine (GEM) given at fixed-dose-rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual. J. Clin. Oncol. 25(Suppl. 18), 4548 (2007).
15. Espinosa E, Feliu J, de Castro J et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic carcinoma. J. Clin. Oncol. 25(Suppl. 18), 15013 (2007).
16. Kim J, Im S, Park E et al. Phase II study of induction chemotherapy with fixed dose rate (FDR) gemcitabine and cisplatin followed by concurrent chemoradiation with capecitabine for locally advanced pancreatic cancer. J. Clin. Oncol. 25(Suppl. 18), 15122 (2007).
17. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol. 17(2), 585-592 (1999).
18. Oettle H, Arning M, Pelzer U et al. A Phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann. Oncol. 11(10), 1267-1272 (2000).
19. Rauch DP, Maurer CA, Aebi S et al. Activity of gemcitabine and continous infusion fluorouracil in advanced pancreatic cancer. Oncology 60(1), 43-48 (2001).
20. Louvet C, Andre T, Hammel P et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann. Oncol. 12(5), 675-679 (2001).
21. Barone C, Cassano A, Corsi DC et al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a Phase I-II study. Oncology 64(2), 139-145 (2003).
22. Marantz A, Jovtis S, Almira E et al. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Semin. Oncol. 28(Suppl. 10), 44-49 (2001).
23. Correale P, Messinese S, Marsili S et al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br. J. Cancer 89(2), 239-242 (2003).
24. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20(15), 3270-3275 (2002).
25. Di Constanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomized Phase II trial of the Italien oncology group for clinical research (GOIRC). Br. J. Cancer 93(2), 185-189 (2005).
26. Riess H, Helm A, Niedergethmann M et al. A randomized, prospective, multicenter, Phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23(S16), 4009 (2005).
27. Cartwright TH, Cohn A, Varkey JA et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 20(1), 160-164 (2002).
28. Hess V, Salzberg M, Borner M et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a Phase I/II trial. J. Clin. Oncol. 21(1), 66-68 (2003).
29. Scheithauer W, Schull B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol. 14(1), 97-104 (2003).
30. Heinemann V, Hoehler T, Seipelt A et al. Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx): a randomized Phase II trial in advanced pancreatic cancer. J. Clin. Oncol. 23(Suppl. 16), 4030 (2005).
31. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer 4 (2005) (Abstract PS11).
32. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG), 2005 ASCO Ann. Meeting Proc. J. Clin. Oncol. 23(Suppl. 16), 4010 (2005).
33. Ueno H, Okusaka T, Ikeda M et al. A Phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69, 421-427 (2005).
34. Ueno H, Okusaka T, Ikeda M et al. An early Phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68, 171-178 (2005).
35. Okusaka T, Funakoshi A, Furuse J et al. A late Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol 61, 615-621 (2008).
36. Kindler HL, Duganm W, Hochster H et al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with permetrexed/ gemcitabine. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 499).
37. Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of permetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16(10), 1639-1645 (2005).
38. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol. 11(11), 1399-1403 (2000).
39. Brodowicz T, Wolfram RM, Kostler WJ et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs 11(8), 623-628 (2000).
40. Philip PA, Zalupski MM, Vaitkevicius VK et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92(3), 569-577 (2001).
41. Cascinu S, Labianca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann. Oncol. 14(2), 205-208 (2003).
42. Heinemann V, Quietzsch D, Gieseler F et al. A Phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 22(Suppl.) (2003) Abstract 1003).
43. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell italia. Meridionale. Cancer 94(4), 902-910 (2002).
44. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) Phase I study. Ann. Oncol. 13(4), 553-557 (2002).
45. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II study. Ann. Oncol. 14(4), 580-585 (2003).
46. Louvet C, Andre T, Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter Phase II study. J. Clin. Oncol. 20(6), 1512-1518 (2002).
47. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509-3516 (2005).
48. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 24(Suppl.18), 4004 (2006).
49. Louvet C, Hincke A, Labianca R et al. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German multicenter Study. J. Clin. Oncol. 24, 179s (2006).
50. Heinemann V, Hinke A, Böck S, Labianca R, Louvet C. Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. J. Clin. Oncol. 25(Suppl.18), 4515 (2007).
51. Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. 20(5), 1182-1191 (2002).
52. Royce ME, Hoff PM, Dumas P et al. Phase I and pharmacokinetic study of exathecan mesylate (DX-8951f): a novel campethecin analog. J. Clin. Oncol. 19, 1493-1500 (2001).
53. Sun FX, Toligo A, Bouvet M et al. Efficacy of camptothecin analog DX 8951f (exathecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 63, 80-85 (2003).
54. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22, 3776-3783 (2004).
55. Abou-Alfa GK, Letourneau R, Harker G et al. Randomized Phase III study of exathecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 24, 4441-4447 (2006).
56. Okada S, Sakata Y, Matsuno S et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer:a Japanese cooperative study. Br. J. Cancer 80, 1377-1379 (1999).
57. Lenzi R, Yalcin S, Evans DB et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 20, 464-470 (2002).
58. Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 12(1), 101-103 (2001).
59. Ryan DP, Kulke MH, Fuchs CS et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94(1), 97-103 (2002).
60. Shepard RC, Levy DE, Berlin JD et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 66(4), 303-309 (2004).
61. Des Guetz G, Chauvenet L, Paraiso D et al. Docetaxel (Do) and gemcitabine (Gem) in advanced pancreatic cancer (APC) patients (pts): a multicentre study. J. Clin. Oncol. 25(Suppl.18), 15065 (2007).
62. Lutz MP, Van Cutsem E, Wagener T et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized Phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J. Clin. Oncol. 23, 9250-9256 (2005).
63. Fine RL, Fogelman DR, Schreibman S et al. GTX chemotherapy for metastatic pancreatic cancer. 2004 ASCO Ann. Meeting Proc. J. Clin. Oncol. 22(Suppl. 18), 380 (2004).
64. Kozuch P, Grossbard ML, Barzdins A et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist6, 488-495 (2001).
65. Rachamalla R, Malamud S, Mathew S et al. Phase I dose-finding of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/ leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anticancer Drugs 15, 211-217 (2004).
66. Goel A, Grossbard ML, Malamud S et al. Pooled efficacy analysis from a Phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs 18, 263-271 (2007).
67. Reni M, Ferreri AJM, Pancci MG et al. Significant improvement of response rate and survival with cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEF-G regimen) in metastatic pancreatic cancer. Eur. J. Cancer 35(Suppl.) (1999) (Abstract 149).
68. Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluororuacil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol. 6, 369-376 (2005).
69. Reni M, Cereda S, Passoni P et al. A randomized Phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma. J. Clin. Oncol. 25(Suppl.18), 4628 (2007).
70. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447-3455 (2001).
71. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167 (2002).
72. Moore MJ, Hamm H, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clincial Trials Group. J. Clin. Oncol. 21, 3296-3302 (2003).
73. Macdonald JS, McCoy S, Whitehead RP et al. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest. New Drugs 23, 485-487 (2005).
74. Van Cutsem E, van de Helde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004).
75. Ozawa F, Friess H, Tempia-Caliera A et al. Growth factors and their receptors in pancreatic cancer. Terat. Carcinog. Mutagen 21, 27-44 (2001).
76. Xiong HQ, Rosenberg A, LoBuglio et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer a multicenter Phase II trial. J. Clin. Oncol. 22, 2610-2616 (2004).
77. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J. Clin. Oncol. 25(Suppl.18), 4059 (2007).
78. Ng SS, Tsao MS, Nicklee T et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, O downstream signaling pathways and apoptosis in human pancreatic adenocarcinom. Mol. Cancer Ther. 1, 777-783 (2002).
79. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007).
80. Van Cutsem E, Verslype C, Grusenmeyer PA et al. Lessons learned in the management of advanced pancreatic cancer. J. Clin. Oncol. 25(15), 1949-1952 (2007).
81. Oettle H, Hilbig A. Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer? Nat. Clin. Pract. Oncol. 4(12), 686-687 (2007).
82. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer 2, 8 (2003).
83. Ikeda N, Adachi M, Taki T et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer 79, 1553-1563 (1999).
84. Seo Y, Baba H, Fukuda T et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88, 2239-2245 (2000).
85. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040 (2006).
86. Kindler HL, Niedzwiecki D, Hollis D et al. A double blind, placebo controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol. 25(Suppl.18), 4508 (2007).
87. Kim GP, Oberg AL, Foster NR et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 25(Suppl. 18), 4553 (2007).
88. Spano J, Chodkiewicz C, Maurel J et al. A randomized Phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a Phase I component. J. Clin. Oncol. 25(Suppl.18), 4551 (2007).
89. Hirano T, Shino Y, Saito T et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 21, 5923-5928 (2002).
90. Wallace JA, Locker G, Nattam S et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a Phase II trial of the University of Chicago Phase II Consortium. J. Clin. Oncol. 25(Suppl.18), 4608 (2007).
91. Ulrich-Pur H, Raderer M, Verena Kornek G et al. Irinotecan plus raltitrexed versus raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic carcinoma. Br. J. Cancer 88, 1180-1184 (2003).
92. Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A Phase II study. Invest. New Drugs 23, 369-375 (2005).
93. Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br. J. Cancer 94, 785-791 (2006).
94. Demols A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a Phase II study. Br. J. Cancer 94, 481-485 (2006).
95. Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11, 635-638 (2000).
96. Burris HA III, Rivkin S, Reynolds R et al. Phase II trial of rubitecan in previously treated pancreatic cancer patients. Oncologist 10, 183-190 (2005).
97. Mitry E, Ducreux M, Ould-Kaci M et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial. Gastroenterol, Clin. Biol. 30, 357-363 (2006).
98. Riess H, Pelzer U, Stieler J et al. A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer-CONKO-003. J. Clin. Oncol. 25(Suppl.18), 4517 (2007).
99. Oettle H, Pelzer U, Stieler J et al. Oxaliplatin/folinic acid/ 5-fluorouracil [24h] (OFF) versus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO-003). J. Clin. Oncol. 23(Suppl.16) 4341 (2005).
100. Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J. Gastroenterol. 13(2), 224-227 (2007).
101. Icli F, Akbulut H, Utkan G et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol. 95, 507-512 (2007).
102. Pelzer U, Hilbig A, Stieler J et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT CONKO-004). J. Clin. Oncol. 24(Suppl.18), 4110 (2006).
103. Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25, 32-42 (2007).
104. Agarwal B, Abu-Hamda E, Molke KL et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am. J. Gastroenterol. 99, 844-850 (2004).
105. Ko A, Scott J, Tempero MA et al. Detection of circulating micrometastases by flow cytometry in patients with pancreatic carcinoma. Presented at: Lustgarten Pancreatic Cancer conference, San Francisco, CA, USA 25-26 June 2004 (Abstract 50).
106. Hoffmann K, Kerner C, Wilfert W et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J. Gastroenterol. 13(2), 257-263 (2007).
107. Shah AN, Summy JM, Zhang J et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. (2007) (In press).
108. Ryther RC, Flynt AS, Phillips JA III, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther. 12, 5-11 (2005).
109. Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Semin. Oncol. 33, 486-497 (2006).
110. Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines 5, 9-19 (2006).
111. Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther. 9(5), 490-497 (2007).
112. Evans T, Ramanathan RK, Yazji S et al. Final results from cohort 1 of a Phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). J. Clin. Oncol. 25(Suppl.18), 4549 (2007).
113. Nugent FW, Cunningham C, Barve MA et al. Phase II study of talabostat/gemcitabine in stage IV pancreatic cancer. J. Clin. Oncol. 25(Suppl.18), 4616 (2007).
114. Khong HAT, Dreisbach L, Kindler HL et al. A Phase II study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. J. Clin. Oncol. 25(Suppl.18), 15017 (2007).